Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT04559854
Other study ID # 20181004
Secondary ID
Status Completed
Phase N/A
First received
Last updated
Start date July 1, 2019
Est. completion date October 5, 2020

Study information

Verified date December 2020
Source Oregon State University
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The objectives of this study are to: 1) adapt a mindfulness-based therapy program designed to help women manage their sexual and body image concerns after cancer (Mindful After Cancer, MAC) to a videoconference format and 2) assess the feasibility, acceptability, and preliminary effects of the program among breast and gynecologic cancer survivors.


Description:

The specific aims are: 1) Assess the feasibility of the MAC program when delivered via videoconference and 2) Assess preliminary effects of the the program.


Recruitment information / eligibility

Status Completed
Enrollment 28
Est. completion date October 5, 2020
Est. primary completion date October 1, 2020
Accepts healthy volunteers No
Gender Female
Age group 18 Years to 89 Years
Eligibility Inclusion Criteria: - Diagnosis of breast or gynecologic cancer at least one year prior to enrollment - English speaking - Have access to a computer, smart phone, or tablet with internet access - Ability to spend 15-30 minutes per day on program activities Exclusion Criteria: - Stage 0 (carcinoma in situ)

Study Design


Related Conditions & MeSH terms


Intervention

Behavioral:
Mindful After Cancer
The intervention includes eight weekly sessions (1.5-2 hours each), plus participant educational materials and audio recorded meditations, and is delivered to women in their homes via group videoconference led by a trained facilitator. Participants are asked to complete activities and mindfulness practice between sessions.

Locations

Country Name City State
United States Oregon State University Corvallis Oregon

Sponsors (2)

Lead Sponsor Collaborator
Oregon State University OHSU Knight Cancer Institute

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Feasibility/ Enrollment Number of participants enrolled, Proportion of participants enrolled of those eligible Baseline
Primary Feasibility/ Retention in Study Number and proportion of participants completing all assessments 1 month post-intervention
Primary Feasibility/ Retention in the Program Mean number of sessions attended, Proportion of participants attending at least 6 of 8 sessions 1 month post-intervention
Primary Acceptability Endorsement of 10 items characterizing acceptability (e.g., the program met my expectations). Range 10-100. Higher score indicates better acceptability. 1 month post-intervention
Secondary Change from baseline self-efficacy at 1 month Self-efficacy for Managing Chronic Disease Scale (adapted). 6 items. Range 6-60. Higher score indicates better self-efficacy for managing sexual health after cancer. Baseline and 1 month post-intervention
Secondary Change from baseline body image at 1 month Body Image Scale. 10 items. Range 0-30. Higher score indicates poorer body image. Baseline and 1 month post-intervention
Secondary Change from baseline body appreciation at 1 month Body Appreciation Scale. 13 items. Range 13-65. Higher score indicates more positive body appreciation. Baseline and 1 month post-intervention
Secondary Change from baseline anxiety at 1 month PROMIS Emotional Distress Anxiety Short Form 6a. 6 items. Range 6-30. Raw scores are translated to a T score following PROMIS guidelines. Higher score indicates greater anxiety symptoms. Baseline and 1 month post-intervention
Secondary Change from baseline depression at 1 month Center for Epidemiologic Studies Depression Scale (CES-D). 20 items. Range 0-60. Higher score indicates greater depressive symptoms Baseline and 1 month post-intervention
Secondary Change in facets of baseline mindfulness at 1 month Five-Facet Mindfulness Questionnaire (FFMQ-15). 15 items with 5 sub-scales: Observe, Describe; Act with Awareness; Non-Judgement, Non-Reactivity. Sub-scale score range 3-15. Higher score indicates greater mindfulness. Baseline and 1 month post-intervention
Secondary Change from baseline self-compassion at 1 month Self-Compassion Scale short form. 12 items. Range 12-60. Higher score indicates greater self-compassion. Baseline and 1 month post-intervention
Secondary Change from baseline relationship quality at 1 month Dyadic Adjustment Scale short form (DAS-7). Range 0-36. Higher score indicates more positive relationship quality Baseline and 1 month post-intervention
Secondary Change from baseline interest in sexual activity at 1 month PROMIS SexFS 2.0. 2 items. Range 2-10. Raw scores are translated to a T score following PROMIS guidelines. Higher score indicates more interest in sexual activity. Baseline and 1 month post-intervention
Secondary Change from satisfaction with sex life at 1 month New Sexual Satisfaction Scale- Short Form (NSSS-S). 12 items. Range 12-60. Higher score indicates more sexual satisfaction. Baseline and 1 month post-intervention
See also
  Status Clinical Trial Phase
Recruiting NCT04681911 - Inetetamab Combined With Pyrotinib and Chemotherapy in the Treatment of HER2 Positive Metastatic Breast Cancer Phase 2
Terminated NCT04066790 - Pyrotinib or Trastuzumab Plus Nab-paclitaxel as Neoadjuvant Therapy in HER2-positive Breast Cancer Phase 2
Completed NCT04890327 - Web-based Family History Tool N/A
Completed NCT03591848 - Pilot Study of a Web-based Decision Aid for Young Women With Breast Cancer, During the Proposal for Preservation of Fertility N/A
Recruiting NCT03954197 - Evaluation of Priming Before in Vitro Maturation for Fertility Preservation in Breast Cancer Patients N/A
Terminated NCT02202746 - A Study to Assess the Safety and Efficacy of the VEGFR-FGFR-PDGFR Inhibitor, Lucitanib, Given to Patients With Metastatic Breast Cancer Phase 2
Active, not recruiting NCT01472094 - The Hurria Older PatiEnts (HOPE) With Breast Cancer Study
Completed NCT06049446 - Combining CEM and Magnetic Seed Localization of Non-Palpable Breast Tumors
Withdrawn NCT06057636 - Hypnosis for Pain in Black Women With Advanced Breast Cancer: A Feasibility Study N/A
Recruiting NCT05560334 - A Single-Arm, Open, Exploratory Clinical Study of Pemigatinib in the Treatment of HER2-negative Advanced Breast Cancer Patients With FGFR Alterations Phase 2
Active, not recruiting NCT05501769 - ARV-471 in Combination With Everolimus for the Treatment of Advanced or Metastatic ER+, HER2- Breast Cancer Phase 1
Recruiting NCT04631835 - Phase I Study of the HS-10352 in Patients With Advanced Breast Cancer Phase 1
Completed NCT04307407 - Exercise in Breast Cancer Survivors N/A
Recruiting NCT03544762 - Correlation of 16α-[18F]Fluoro-17β-estradiol PET Imaging With ESR1 Mutation Phase 3
Terminated NCT02482389 - Study of Preoperative Boost Radiotherapy N/A
Enrolling by invitation NCT00068003 - Harvesting Cells for Experimental Cancer Treatments
Completed NCT00226967 - Stress, Diurnal Cortisol, and Breast Cancer Survival
Recruiting NCT06019325 - Rhomboid Intercostal Plane Block on Chronic Pain Incidence and Acute Pain Scores After Mastectomy N/A
Recruiting NCT06006390 - CEA Targeting Chimeric Antigen Receptor T Lymphocytes (CAR-T) in the Treatment of CEA Positive Advanced Solid Tumors Phase 1/Phase 2
Recruiting NCT06037954 - A Study of Mental Health Care in People With Cancer N/A